Lowering serum urate levels with allopurinol did not improve kidney outcomes in patients with type 1 diabetes
Randomized trial participants with type 1 diabetes and mild-to-moderate diabetic kidney disease who received allopurinol or placebo had similar estimated glomerular filtration rates after three years.
Continuous glucose monitoring (CGM) was associated with improved HbA1c levels among adolescents and young adults in one trial and less hypoglycemia among older adults in another.
Patients with type 2 diabetes who had no diabetes-related polyneuropathy, diabetes-related polyneuropathy with pain, and diabetes-related polyneuropathy without pain were compared in an industry-funded retrospective study.
A systematic review and network meta-analysis found no differences between treatments for drug-naive patients with type 2 diabetes at low cardiovascular risk, leading the authors to conclude that metformin is justified as a first-line therapy.